OP 8.4 – 00165 TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption

• H. King,
• D. Brammer,
• C. Lehman,
• M. Roederer,
• D. Bolton,
• R. Mason,
• K. Song,
• K. Foulds,
• J. Lifson,
• P. Darrah,
• R. Geleziunas

Affiliations

H. King

U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

D. Brammer

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

C. Lehman

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

M. Roederer

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

D. Bolton

U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA

R. Mason

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

K. Song

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

K. Foulds

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

J. Lifson

AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, USA

P. Darrah

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

R. Geleziunas

Gilead Sciences, Foster City, CA, USA